BBIO$76.26
$77.43
Chart
Performance
Key Stats
AI BBIO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBridgeBio Pharma shows strong fundamental potential driven by its innovative pipeline, although current market conditions and short-term technicals warrant a cautious approach. Long-term prospects remain promising.
Thematic
Positioned in the biopharmaceutical sector, BridgeBio Pharma benefits from secular tailwinds in genetic disease and oncology treatments. However, the competitive landscape and regulatory hurdles introduce significant risk.
Fundamental
BridgeBio Pharma has a robust balance sheet and significant cash reserves, but its profitability is challenged by substantial operating expenses and a lack of approved products generating revenue. The focus is on long-term pipeline value.
Technical
The stock has experienced recent volatility and is trading below its key moving averages, indicating a neutral to slightly bearish short-term outlook. Momentum indicators suggest a potential for stabilization or a slight rebound.
| Factor | Score |
|---|---|
| Genetic Disease Treatment Focus | 85 |
| Oncology Innovation | 75 |
| Biotech Sector Growth | 80 |
| Regulatory Environment | 40 |
| Competition | 55 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 95 |
| Balance Sheet Health | 75 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 70 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Recent Performance
The stock has shown positive performance over multiple periods, with a 1.2% gain in the last month and a significant 68.8% gain over the past year.
Growth Potential Indicated by Price/Sales
The trailing 12-month Price/Sales (PS) ratio is 69.2, which, while high, needs to be considered in conjunction with the company's stage of development and growth prospects. Further analysis is needed to determine if this is justified.
Bearish Points (7)
Negative Earnings Per Share (EPS)
The company consistently reports negative EPS (e.g., -3.56 TTM, -0.88 in Q2 2025), indicating a lack of profitability. This is typical for early-stage biopharmaceutical companies but presents a significant risk.
High Price-to-Sales Ratio
The trailing 12-month Price/Sales (PS) ratio of 69.2 is extremely high, suggesting the company is valued primarily on future potential rather than current revenue generation, which carries substantial risk.
Calendar
August 2025
6
Next Earnings Date
H: $-0.34
A: $-0.42
L: $-0.50
H: 182.40M
A: 98.46M
L: 55.00M
Profile
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Seasonals
Price Target
61.50 USD
The 39 analysts offering 1 year price forecasts for BBIO have a max estimate of 95.00 and a min estimate of 41.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in the development and commercialization of therapies for rare and ultra-rare genetic diseases, operating with a similar focus on high-unmet-need conditions.
Weight: 95
Pioneering company in RNA interference (RNAi) therapeutics, with multiple approved drugs and a strong pipeline addressing rare genetic diseases, similar to BridgeBio's genetic focus.
Weight: 92
Leading biotech in rare disease drug development, particularly known for cystic fibrosis, and expanding into other genetic and serious diseases with advanced therapeutic modalities.
Weight: 90
A well-established biopharmaceutical company dedicated exclusively to the development and commercialization of therapies for rare genetic diseases, a direct thematic peer.